Company news
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) news
Whitehawk Therapeutics, Inc. news releases on 6ix. Latest, Oct 1, 2026: Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC…
Press releases & updates
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
September 30, 2026
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
October 1, 2026
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
September 12, 2026
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
September 10, 2026
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
July 6, 2026
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
May 30, 2026
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
May 28, 2026
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
May 21, 2026
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
May 20, 2026
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
May 15, 2026
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
May 13, 2026
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 7, 2026
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
April 19, 2026
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
April 16, 2026
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
April 10, 2026
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
March 16, 2026
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
March 11, 2026
Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
January 11, 2026
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
January 8, 2026
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
December 1, 2025
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London
November 11, 2025
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 6, 2025
Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
October 24, 2025
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
October 15, 2025
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
September 2, 2025
Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
August 7, 2025
Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
July 22, 2025
Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series
June 19, 2025
Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference
May 28, 2025
Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit
May 21, 2025
Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights
May 8, 2025
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals
March 26, 2025
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update
March 13, 2025
Aadi Bioscience Announces Closing of $100 Million PIPE Financing
March 3, 2025
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders
March 2, 2025
Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference
February 23, 2025
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer
February 17, 2025
Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025
February 4, 2025
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing
December 18, 2024
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update
November 5, 2024
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update
October 29, 2024
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
August 19, 2024
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update
August 6, 2024
Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update
July 30, 2024
Aadi Bioscience to Participate in the Jefferies Healthcare Conference
May 28, 2024
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2024
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
May 7, 2024
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
April 30, 2024